Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $8.75.

A number of equities analysts recently weighed in on RANI shares. Wall Street Zen raised Rani Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, May 17th. HC Wainwright reiterated a “buy” rating on shares of Rani Therapeutics in a report on Friday, August 21st. Weiss Ratings downgraded shares of Rani Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. Chardan Capital raised shares of Rani Therapeutics to a “strong-buy” rating in a research report on Wednesday. Finally, Canaccord Genuity Group restated a “buy” rating and set a $5.00 price target on shares of Rani Therapeutics in a report on Wednesday, May 20th.

Rani Therapeutics Stock Performance

Shares of NASDAQ:RANI opened at $0.84 on Friday. Rani Therapeutics has a one year low of $0.44 and a one year high of $3.87. The stock has a fifty day moving average of $0.78 and a 200-day moving average of $0.95. The company has a market capitalization of $117.10 million, a PE ratio of -3.11 and a beta of 0.78.

Rani Therapeutics (NASDAQ:RANI) last issued its earnings results on Thursday, August 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The company had revenue of $1.71 million during the quarter, compared to analyst estimates of $0.93 million. As a group, research analysts forecast that Rani Therapeutics will post -0.17 EPS for the current fiscal year.

Insider Transactions at Rani Therapeutics

In other news, CEO Talat Imran bought 35,000 shares of the business’s stock in a transaction on Friday, July 17th. The shares were bought at an average cost of $0.72 per share, with a total value of $25,200.00. Following the purchase, the chief executive officer directly owned 469,736 shares in the company, valued at $338,209.92. This trade represents a 8.05% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 26.73% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Armistice Capital LLC acquired a new position in Rani Therapeutics during the second quarter valued at $1,619,000. Citadel Advisors LLC boosted its position in Rani Therapeutics by 199.0% during the 3rd quarter. Citadel Advisors LLC now owns 452,542 shares of the company’s stock worth $226,000 after acquiring an additional 301,193 shares during the period. Kestra Private Wealth Services LLC grew its stake in Rani Therapeutics by 44.8% during the 3rd quarter. Kestra Private Wealth Services LLC now owns 226,142 shares of the company’s stock valued at $113,000 after acquiring an additional 70,002 shares in the last quarter. Jefferies Financial Group Inc. purchased a new position in Rani Therapeutics during the 4th quarter valued at about $40,000. Finally, Geode Capital Management LLC increased its holdings in shares of Rani Therapeutics by 190.0% in the 4th quarter. Geode Capital Management LLC now owns 860,941 shares of the company’s stock valued at $1,163,000 after purchasing an additional 564,031 shares during the period. Hedge funds and other institutional investors own 30.19% of the company’s stock.

Rani Therapeutics Company Profile

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.